It clearly indicates the Hemostasis Market is moving in the direction of Automation quite strongly and fast.
Automation may happen in several contexts: from the automation of several procedures (pre-analytical checks of samples, autorun of tests, generation of reports, etc.) ensured with the adoption of the ACL TOP® 50Family; to logical automation (multi-step analysis based on published Algorithms, Centralization and Standardization of samples management, etc.) through HemoHub® - Intelligent Data Manager; to complete automation of physical movement of samples and logics that are unique for the Hemostasis Laboratory with the HemoCell® solution that combines Thermo Fisher Scientific physical modules, ACL TOP 750 LAS® and as a core components of it, HemoHub®.
The consulting approach that Werfen has adopted is helping to define the right solution for the user, identifying areas of improvement in the lab performing Workflow analysis and according with the Solutions Werfen is proposing.
As part of the empowerment of Werfen Automation strategy, and following the successful 2023 EEMEA Partnership Meeting initiatives, the next HemoHub® Application and Commercial training in Milan is going to happen in October: click HERE (Link) for details.
The training will be focused on Commercial and Promotional Tools, on the right usage of the available resources to succeed in the HemoHub® and HemoCell® presentation, on some aspects of project management and it’s also including a basic application training to learn how to setup the solution and being ready for future installations in cross-collaboration with the Team in Milan Hub.
As of today, the numbers of HemoHub training have been really amazing: more than 30 people, from 19 different countries, but as Pepe Zamora (VP Commercial Operations EEMEA) is used to say, “The best is yet to come!”, and we expect to have more and more people enrolling to our training.
All those efforts have the objective of extending as much as possible the adoption of HemoHub® and HemoCell® arriving first in the market and as a further competitive option in our Portfolio.
Gianpaolo Pozzato, Product Manager Hemostasis EEMEA



